216 related articles for article (PubMed ID: 10523073)
1. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
Giverhaug T; Loennechen T; Aarbakke J
Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Ogungbenro K; Aarons L;
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
[TBL] [Abstract][Full Text] [Related]
3. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
[TBL] [Abstract][Full Text] [Related]
4. Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children.
de Beaumais TA; Jacqz-Aigrain E
Curr Drug Metab; 2012 Jul; 13(6):822-34. PubMed ID: 22571483
[TBL] [Abstract][Full Text] [Related]
5. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.
Innocenti F; Danesi R; Di Paolo A; Loru B; Favre C; Nardi M; Bocci G; Nardini D; Macchia P; Del Tacca M
Cancer Chemother Pharmacol; 1996; 37(5):409-14. PubMed ID: 8599862
[TBL] [Abstract][Full Text] [Related]
6. A mathematical model of white blood cell dynamics during maintenance therapy of childhood acute lymphoblastic leukemia.
Le TTT; Jost F; Raupach T; Zierk J; Rauh M; Suttorp M; Stanulla M; Metzler M; Sager S
Math Med Biol; 2019 Dec; 36(4):471-488. PubMed ID: 30357334
[TBL] [Abstract][Full Text] [Related]
7. Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.
Keuzenkamp-Jansen CW; De Abreu RA; Blom HJ; Bökkerink JP; Trijbels JM
Biochem Pharmacol; 1996 May; 51(9):1165-71. PubMed ID: 8645339
[TBL] [Abstract][Full Text] [Related]
8. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
[TBL] [Abstract][Full Text] [Related]
9. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia.
Shuper A; Stark B; Kornreich L; Cohen IJ; Avrahami G; Yaniv I
Isr Med Assoc J; 2002 Nov; 4(11):1050-3. PubMed ID: 12489505
[TBL] [Abstract][Full Text] [Related]
11. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
Hayder S; Björk O; Lafolie P
Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
[TBL] [Abstract][Full Text] [Related]
12. Importance of oral antimetabolite "maintenance" therapy in childhood lymphoblastic leukemia.
Lilleyman JS
Pediatr Hematol Oncol; 1996; 13(5):vii-x. PubMed ID: 10897808
[No Abstract] [Full Text] [Related]
13. On the biochemical modulation of 6-mercaptopurine by methotrexate in murine WEHI-3b leukemia cells in vitro.
Liliemark J; Pettersson B; Peterson C
Leuk Res; 1992; 16(3):275-80. PubMed ID: 1373210
[TBL] [Abstract][Full Text] [Related]
14. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RA; Schretlen ED
Biochem Pharmacol; 1988 Jun; 37(12):2321-7. PubMed ID: 2455519
[TBL] [Abstract][Full Text] [Related]
15. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
[TBL] [Abstract][Full Text] [Related]
16. Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic.
Evans WE; Pui CH; Relling MV
Adv Exp Med Biol; 1999; 457():537-41. PubMed ID: 10500831
[No Abstract] [Full Text] [Related]
17. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
18. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
19. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
20. Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?
Evans WE; Relling MV; Boyett JM; Pui CH
Leuk Res; 1997 May; 21(5):435-7. PubMed ID: 9225072
[No Abstract] [Full Text] [Related]
[Next] [New Search]
